Assay for human breast cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 7, 1989
Grant Date -
N/A
app pub date -
Feb 5, 1986
filing date -
Feb 5, 1986
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Methods are disclosed for detecting, staging and monitoring breast cancer. The methods involve determining the amount of certain antigens, designated W1 and W9, in serum via quantitative immunoassays using anti-W1 or anti-W9 monoclonal antibodies. The amount detected is compared with amounts of the antigen found in normal sera, sera from breast cancer patients of predetermined stage, or other samples of the patient's own serum, depending upon the purpose of the assay.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully